AU2003267347A1 - Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell - Google Patents

Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell

Info

Publication number
AU2003267347A1
AU2003267347A1 AU2003267347A AU2003267347A AU2003267347A1 AU 2003267347 A1 AU2003267347 A1 AU 2003267347A1 AU 2003267347 A AU2003267347 A AU 2003267347A AU 2003267347 A AU2003267347 A AU 2003267347A AU 2003267347 A1 AU2003267347 A1 AU 2003267347A1
Authority
AU
Australia
Prior art keywords
amyloid
identifying
cell
compound
changes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003267347A
Other languages
English (en)
Inventor
Marcel Hoffmann
Wendy Laenen
Pascal Gerard Merchiers
Koenraad Frederik Florentina Spittaels
Kim Thys
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos Genomics NV
Original Assignee
Galapagos Genomics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Genomics NV filed Critical Galapagos Genomics NV
Publication of AU2003267347A1 publication Critical patent/AU2003267347A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003267347A 2003-09-10 2003-09-10 Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell Abandoned AU2003267347A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/010160 WO2005024057A1 (fr) 2003-09-10 2003-09-10 Procede pour identifier un compose qui modifie le traitement d'une proteine precurseur de la beta-amyloide dans une cellule

Publications (1)

Publication Number Publication Date
AU2003267347A1 true AU2003267347A1 (en) 2005-03-29

Family

ID=34259125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003267347A Abandoned AU2003267347A1 (en) 2003-09-10 2003-09-10 Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell

Country Status (2)

Country Link
AU (1) AU2003267347A1 (fr)
WO (2) WO2005024057A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198912B2 (en) 2001-09-07 2007-04-03 Bristol-Myers Squibb Company Polynucleotides encoding a human G-protein coupled receptor, HGPRBMY39
WO2005047899A2 (fr) * 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Utilisation d'un recepteur de lipoxine, fprl1, en tant qu'outil d'identification de composes efficaces dans le traitement de douleurs et d'inflammations
US7671028B2 (en) * 2004-02-04 2010-03-02 Postech Foundation Peptides that antagonize FPR class receptor mediated signaling
WO2005103255A1 (fr) * 2004-03-25 2005-11-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recepteur formylpeptide (fpr) utilise en tant que cible pour une therapie anti-gliome malin
WO2005103708A1 (fr) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostic et traitement de maladies associees recepteur couple a la proteine g humaine ressemblant a gpr-32
WO2005106490A1 (fr) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Agents diagnostiques et therapeutiques pour maladies associees au recepteur 1 de type chimiokine (cmklr1)
WO2008028250A1 (fr) * 2006-09-08 2008-03-13 Autogen Research Pty Ltd Agents thérapeutiques, cibles et diagnostique
CN101586103B (zh) * 2009-06-25 2010-12-08 上海交通大学 胰高血糖素受体基因的rna干扰序列
CN104258371B (zh) * 2014-09-25 2016-06-15 中山大学 Www三肽在制备治疗阿尔茨海默症药物中的用途
CN104274817B (zh) * 2014-09-25 2016-06-15 中山大学 Wrw三肽在制备治疗阿尔茨海默症药物中的用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1278844A2 (fr) * 2000-05-03 2003-01-29 PHARMACIA & UPJOHN COMPANY Nouveaux recepteurs couples a la proteine g
EP1326975A2 (fr) * 2000-10-06 2003-07-16 Bayer Aktiengesellschaft Regulation du recepteur de secretine humaine de type gpcr
WO2002044212A2 (fr) * 2000-11-30 2002-06-06 Deleersnijder, Willy Recepteur couple aux proteines g humaines et ses utilisations
AU2002336759A1 (en) * 2001-09-21 2003-04-14 Accera, Inc. Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism
US20030096260A1 (en) * 2001-10-09 2003-05-22 Zhenhua Miao Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof
DE10151511A1 (de) * 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
AU2003206749A1 (en) * 2002-02-01 2003-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with the gpr65 receptor
EP1474139B1 (fr) * 2002-02-01 2007-11-21 Merck & Co., Inc. Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase 1 utiles pour le traitement du diabete, de l'obesite et de la dyslipidemie
AU2003214072A1 (en) * 2002-03-07 2003-09-16 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
EP1487473A2 (fr) * 2002-03-22 2004-12-22 Bayer HealthCare AG Diagnostics et therapeutiques associes au recepteur 2 du peptide de formyle humain
WO2003082314A2 (fr) * 2002-04-03 2003-10-09 Bayer Healthcare Ag Diagnostics et therapies pour maladies liees a un recepteur de type 1 de peptides n-formyl (fprl1)
WO2003096024A1 (fr) * 2002-05-08 2003-11-20 Bayer Healthcare Ag Diagnostics et traitements pour maladies associees au recepteur 2 du peptide intestinal vasoactif (vpac2)
EP1539136B1 (fr) * 2002-07-30 2008-07-09 Merck & Co., Inc. Composes selectifs des recepteurs ppar alpha destines au traitement de la dyslipidemie et d'autres troubles lipidiques
DE60332738D1 (de) * 2002-07-30 2010-07-08 Merck Sharp & Dohme Ppar alpha selektive verbindungen zur behandlung von dyslipidämie und anderen lipidstörungen
WO2004094636A1 (fr) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Constructions demontables effectives d'arnsi

Also Published As

Publication number Publication date
WO2005024058A2 (fr) 2005-03-17
WO2005024058A3 (fr) 2005-11-10
WO2005024057A1 (fr) 2005-03-17

Similar Documents

Publication Publication Date Title
AU2003252093A1 (en) Computer-implemented system for automated trading
AU2003203090A1 (en) Method for distinguishing between protein variants
AU2003234608A1 (en) Automated dialysis system
GB0406871D0 (en) Systems and methods for automated internet-based auctions
WO2004097734A8 (fr) Procede pour traiter des donnees
AU2003290321A1 (en) Cell cycle progression proteins
AU2003256375A1 (en) Automated trading system
AU2003228482A1 (en) Automated protein crystallization imaging
AU2003302061A1 (en) Motor and method for manufacturing motor
AU2003289449A1 (en) Method for manufacturing display
AU2003283174A1 (en) Method for protein production
AU2003263606A1 (en) Surface processing method
AU2002952747A0 (en) Method for analysing peptides
AU2003289445A1 (en) Method for manufacturing display
AU2003220322A1 (en) Methods for identifying polypeptide factors interacting with rna
AU2003267347A1 (en) Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell
AU2003298171A1 (en) Protein complexes associated with app-processing
AU2003207200A1 (en) Polarization analyzing method
AU2003251958A1 (en) Warranty managing process
EP1603386B8 (fr) Procede d'aquaculture
AU2003205259A1 (en) Process for finish-abrading optical-fiber-connector end-surface
AU2003901196A0 (en) Analysis method
AU2003216370A1 (en) Assays to monitor amyloid precursor protein processing
AUPS306402A0 (en) Assay method
AU2003256469A1 (en) Method for distinguishing between biomolecule and non-biomolecule crystals

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase